Literature DB >> 10620654

The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease.

C Choi1, Y H Sohn, J H Lee, J Kim.   

Abstract

20) became non-depressed, while five patients (22%) among 23 initially non-depressed became depressed. With long-term levodopa therapy, the UPDRS-motor score significantly improved (35+/-15. 7-18+/-7.6), but the BDI score was unchanged (18+/-9.3-19+/-9.2). The initial BDI score was significantly and inversely correlated to the parkinsonian motor symptoms, but their percentage changes were not correlated to each other. These results provide strong support to previous observations that levodopa therapy does not alter parkinsonian depression as well as providing additional evidence to support the role of non-dopaminergic mechanisms in parkinsonian depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620654     DOI: 10.1016/s0022-510x(99)00198-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 2.  A practical approach to detection and treatment of depression in Parkinson disease and dementia.

Authors:  Zahra Goodarzi; Zahinoor Ismail
Journal:  Neurol Clin Pract       Date:  2017-04

3.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

4.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

Review 5.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

6.  Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  2014-09-11       Impact factor: 4.030

7.  Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model.

Authors:  Se Jong Oh; Heesu Ahn; Ki-Hye Jung; Sang Jin Han; Kyung Rok Nam; Kyung Jun Kang; Ji-Ae Park; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

8.  Mathematical insights into the effects of levodopa.

Authors:  Michael C Reed; H Frederik Nijhout; Janet A Best
Journal:  Front Integr Neurosci       Date:  2012-07-04

Review 9.  Mixed effects of deep brain stimulation on depressive symptomatology in Parkinson's disease: a review of randomized clinical trials.

Authors:  N Simay Gökbayrak; Irene Piryatinsky; Rebecca A Gavett; Omar J Ahmed
Journal:  Front Neurol       Date:  2014-08-11       Impact factor: 4.003

10.  Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease.

Authors:  Alexandru Hanganu; Clotilde Degroot; Oury Monchi; Christophe Bedetti; Béatriz Mejia-Constain; Anne-Louise Lafontaine; Sylvain Chouinard; Marie-Andrée Bruneau
Journal:  Front Neurol       Date:  2014-09-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.